Related Experiment Video
Updated: Jan 28, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
Inclisiran in Dyslipidemia with High Residual Platelet Reactivity
Dina Kapsultanova1, Sholpan Zhangelova1, Friba Nurmukhammad2
1Faculty of Postgraduate Education, Asfendiyarov Kazakh National Medical University, Almaty 050012, Kazakhstan.
Inclisiran effectively lowers LDL-C and may improve platelet reactivity in high-risk patients with dyslipidemia and high residual platelet reactivity (HRPR) despite standard therapies. Further research is needed to confirm clinical outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Vascular Biology
Background:
- High residual platelet reactivity (HRPR) and persistent dyslipidemia are key challenges in cardiovascular risk management, especially post-revascularization.
- Many patients fail to meet low-density lipoprotein cholesterol (LDL-C) targets or achieve adequate platelet inhibition with current treatments.
- Inclisiran, a novel siRNA targeting PCSK9, offers a new therapeutic avenue for sustained LDL-C reduction.
Purpose of the Study:
- To review the efficacy of inclisiran in patients with dyslipidemia and HRPR who have an insufficient response to conventional therapies.
- To explore the potential impact of inclisiran on platelet reactivity in high-risk cardiovascular patients.
- To highlight the role of platelet function assessment in identifying residual thrombotic risk.
Main Methods:
- A narrative literature review (2009-2025) was conducted using major scientific databases (PubMed, Scopus, Web of Science, MEDLINE).
- Included studies focused on inclisiran's addition to standard lipid-lowering therapy in patients with dyslipidemia and HRPR, assessed via the VerifyNow assay.
- Real-world clinical cases from Kazakhstan were analyzed to illustrate treatment effects.
Main Results:
- Inclisiran consistently achieves significant and sustained reductions in LDL-C and PCSK9 levels.
- Emerging data suggest inclisiran may indirectly modulate platelet reactivity, particularly in patients with extreme cardiovascular risk.
- In patients post-CABG or with extensive CAD, inclisiran showed marked LDL-C reduction and a trend towards normalized platelet reactivity.
Conclusions:
- The VerifyNow assay can aid in identifying residual thrombotic risk in patients with advanced atherosclerotic disease.
- Inclisiran shows promise as an adjunctive therapy for dyslipidemic patients with persistent cardiovascular risk and HRPR.
- Further prospective studies are essential to elucidate the interplay between LDL-C reduction, platelet function, and clinical outcomes.
More Related Videos
06:35Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research
Published on: March 29, 2024
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
Related Concept Videos
Residual Stresses
Residual Plots
When the residual values are plotted against the variable x, it is called a residual...
Residual Stresses in Circular Shafts
Residual Stresses in Bending
Residuals and Least-Squares Property
If the observed data point lies above the line, the residual is positive, and the line underestimates the actual data value for y. If the observed data point lies below the line, the residual is negative, and the line overestimates the actual data value for y.
The process of fitting the best-fit...
Cross-reactivity